BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host disease. But a patient death raises the possibility allogeneic...
BioCentury | Oct 8, 2020
Finance

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

Genor’s $371 million IPO on the Hong Kong stock exchange’s prerevenue chapter Wednesday caps a busy 12 months for the Shanghai cancer company during which it has rebooted its C-suite, added dry powder via a...
BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

Incyte moving into Phase III with PD-1 inhibitor retifanlimab for SCACIncyte Corp. (NASDAQ:INCY) reported its PD-1 inhibitor retifanlimab led to an objective response rate of 14% and a disease control rate of 49% in the...
BioCentury | Sep 16, 2020
Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

MorphoSys’ first marketed therapeutic, Monjuvi, has the makings of a blockbuster, but the company and partner Incyte will need to execute on the drug’s launch and planned label expansions to generate the...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s $115 million series C round.  Additional new investors Lilly...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Antisense-mediated exon skipping for X-linked Alport syndrome

DISEASE CATEGORY: Renal INDICATION: Renal Exon skipping therapy with an antisense oligonucleotide (ASO) targeting a truncating variant in exon 21 of COL4A5 could treat severe X-linked Alport syndrome. The ASO led to complete exon 21...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

Two of China’s most prominent immuno-oncology companies made moves this week to bolster their CAR T cell therapy pipelines: one via a deal and the other with a financing. Innovent Biologics Inc. (HKSE:1801) has acquired...
BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

...other end of the fusion proteins deliver a negative regulator protein, either factor H or CR1...
...complement pathway, like anti-C5 mAb Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), factor H and CR1...
...Broxson Patents: Undisclosed Targets C3 - Complement 3 C5 - Complement 5 CR1 (CD35) - Complement receptor 1...
Items per page:
1 - 10 of 1347